People suffering from severe migraines in Scotland will be able to get treatment with Amgen and Novartis’ Aimovig if they fail other therapies, according to the country’s cost-effectiveness
Novartis and Amgen have become embroiled in a legal row over rights to the migraine prevention drug Aimovig, as sales of a new class of injected drugs begin to mount.
For episode 7 of the pharmaphorum podcast I spoke to Ipsen’s Philippe Picaut about neurotoxin research, with a particular focus on Botulinum neurotoxins.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.